ATE478076T1 - Azaxanthonen zur behandlung von tumoren - Google Patents

Azaxanthonen zur behandlung von tumoren

Info

Publication number
ATE478076T1
ATE478076T1 AT06851384T AT06851384T ATE478076T1 AT E478076 T1 ATE478076 T1 AT E478076T1 AT 06851384 T AT06851384 T AT 06851384T AT 06851384 T AT06851384 T AT 06851384T AT E478076 T1 ATE478076 T1 AT E478076T1
Authority
AT
Austria
Prior art keywords
tumors
azaxanthones
treatment
mesenchymel
retarding
Prior art date
Application number
AT06851384T
Other languages
English (en)
Inventor
Grzegorz Pietrzynski
Valery Alakhov
Alexandre Semov
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Application granted granted Critical
Publication of ATE478076T1 publication Critical patent/ATE478076T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06851384T 2005-12-13 2006-12-12 Azaxanthonen zur behandlung von tumoren ATE478076T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/301,930 US7772255B2 (en) 2005-12-13 2005-12-13 Method of treating tumors with azaxanthones
PCT/IB2006/004291 WO2008020269A2 (en) 2005-12-13 2006-12-12 A method of treating tumors with azaxanthones

Publications (1)

Publication Number Publication Date
ATE478076T1 true ATE478076T1 (de) 2010-09-15

Family

ID=38140264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06851384T ATE478076T1 (de) 2005-12-13 2006-12-12 Azaxanthonen zur behandlung von tumoren

Country Status (8)

Country Link
US (2) US7772255B2 (de)
EP (1) EP1968981B1 (de)
JP (1) JP2009519318A (de)
AT (1) ATE478076T1 (de)
CA (1) CA2633112A1 (de)
DE (1) DE602006016333D1 (de)
HK (1) HK1116186A1 (de)
WO (1) WO2008020269A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089707A1 (en) * 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
CN101899051B (zh) * 2010-05-17 2013-03-20 中国人民解放军第二军医大学 1-氮杂呫吨酮-3-甲酰胺类化合物及制备方法和抗肿瘤用途
CN103189060A (zh) * 2010-08-05 2013-07-03 里尔法律与医疗卫生第二大学 用于对无义突变介导的疾病进行治疗的化合物和含有所述化合物的药物组合物
ES2659763T3 (es) * 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
ES2727898T3 (es) 2013-05-02 2019-10-21 Univ Michigan Regents Amlexanox deuterado con estabilidad metabólica mejorada
EP3405587A4 (de) 2015-12-23 2019-10-30 Moonshot Pharma LLC Verfahren zur auslösung einer immunreaktion durch read-through-förderung eines vorzeitigen terminationscodons
EP3407974A4 (de) * 2016-01-29 2019-08-28 The Regents Of The University Of Michigan Amlexanox-analoga
US11654135B2 (en) 2017-06-22 2023-05-23 Moonshot Pharma Llc Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
CN109718374B (zh) * 2017-10-27 2022-03-08 中国科学院分子细胞科学卓越创新中心 Irf3抑制剂在制备yap过度激活的癌症的治疗或预防药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1087188A (en) 1977-03-08 1980-10-07 Hirosada Sugihara 1-azaxanthone-3-carboxylic acids
JPS53111096A (en) * 1977-03-08 1978-09-28 Takeda Chem Ind Ltd 1-azaxanthone-3-carboxylic acid derivative and its preparation
US4539326A (en) * 1982-08-20 1985-09-03 Takeda Chemical Industries, Ltd. 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents
JP2963496B2 (ja) * 1989-06-26 1999-10-18 第一製薬株式会社 ベンゾピラノピリジン誘導体
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
KR100866820B1 (ko) * 2000-07-13 2008-11-04 다케다 야쿠힌 고교 가부시키가이샤 지질 풍부 플라크 퇴축제
US20020103219A1 (en) * 2000-10-05 2002-08-01 Jeremy Jacob Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders
DE10250081A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Vetmedica Gmbh Wasserlösliche Meloxicam Granulate
EP1569942A2 (de) * 2002-12-12 2005-09-07 Pharmacia Corporation Tricyclische aminocyanopyridininhibitoren von mitogenaktivierter proteinkinaseaktivierter proteinkinase-2

Also Published As

Publication number Publication date
US20090042923A1 (en) 2009-02-12
WO2008020269A3 (en) 2008-07-24
US7772255B2 (en) 2010-08-10
WO2008020269A2 (en) 2008-02-21
DE602006016333D1 (de) 2010-09-30
CA2633112A1 (en) 2008-02-21
EP1968981B1 (de) 2010-08-18
EP1968981A2 (de) 2008-09-17
US20070135473A1 (en) 2007-06-14
JP2009519318A (ja) 2009-05-14
EP1968981A4 (de) 2009-04-15
HK1116186A1 (en) 2008-12-19

Similar Documents

Publication Publication Date Title
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
CY1117655T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
DE602006014843D1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
CY1116728T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
DE602004024909D1 (de) Platinkomplexe zur behandlung von tumoren
GEP20237458B (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
CY1117423T1 (el) Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
ATE526987T1 (de) Dr5-antikörper und deren verwendung
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
NO20064794L (no) Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon
BRPI0407234A (pt) Heterociclos substituìdos
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
DE602005025459D1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
DE60212415D1 (de) Die verwendung von einer 4-pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties